Form 4: Verona Pharma Director Mahendra Shah Awarded 96,000 Restricted Share Units
SEC Form 4
Director Mahendra Shah receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.
Summary
- Mahendra Shah, a director of Verona Pharma plc, was awarded 96,000 Restricted Share Units (RSUs) on April 25, 2025.
- Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight ordinary shares of Verona Pharma.
- The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026.
- Vesting is contingent upon Mr. Shah's continued service to Verona Pharma on each vesting date.
- The price of the derivative security is $0.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice that aligns management and shareholder interests. The vesting schedule is typical and doesn't raise any immediate concerns.
Positives
- The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
Risks
- The value of the RSUs is dependent on the future performance of Verona Pharma's stock price, which is subject to market risks and company-specific factors.
Future Outlook
The vesting of the RSUs is contingent upon the director's continued service, suggesting an expectation of ongoing involvement with the company.
Industry Context
Granting RSUs to directors is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.
Stakeholder Impact
- Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
- The director is incentivized to remain with the company and contribute to its growth.
Key Dates
| Date | Description |
|---|---|
| 04/25/2025 | Date of the RSU transaction. |
| 08/01/2025 | First vesting date for 25% of the RSUs. |
| 11/01/2025 | Second vesting date for 25% of the RSUs. |
| 02/01/2026 | Third vesting date for 25% of the RSUs. |
| 05/01/2026 | Final vesting date for 25% of the RSUs. |
| 04/29/2025 | Date of the form filing. |
Keywords
Verona Pharma, Restricted Share Units, RSU, Director, Mahendra Shah, Beneficial Ownership, Form 4, VRNA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.